A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Study Overview

The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).

Study Description

The purpose of this study is to assess if continuation therapy with atezolizumab in combination with next-line chemotherapy (carboplatin + gemcitabine) will improve PFS in patients with cisplatin-ineligible metastatic urothelial carcinoma as compared to historical controls.

  • IRB Number: 1809401454 (GU17-295)
  • Research Study Identifier: TX9408
  • Principal Investigator: Nabil Adra, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.